Outcomes for patients starting a new treatment for inflammatory bowel disease are characterized by uncertainty of treatment response. Although it is natural to hope that new treatments will be characterized by better efficacy, remission is still far from a universal experience for patients living with inflammatory bowel disease. At times, an apparent “glass ceiling” appears to constrain progress toward a goal of maximal long-term health care–related quality of life for all. There are a number of areas that can and should be addressed if we are to make significant progress. These range from improved early diagnosis and initial management through better treatment stratification and response monitoring, to improvements in clinical trial design and selection of drugs in combination therapies. In this article, we discuss the steps required in all of these areas to make best use of new therapeutic options and shatter the glass ceiling.

中文翻译：

---

突破治疗天花板：需要什么？


开始炎症性肠病新治疗的患者的结果特点是治疗反应的不确定性。尽管人们自然希望新的治疗方法具有更好的疗效，但对于炎症性肠病患者来说，缓解仍远未达到普遍的效果。有时，明显的“玻璃天花板”似乎限制了实现所有人长期医疗保健相关生活质量最大化目标的进展。如果我们要取得重大进展，有许多领域可以而且应该解决。这些范围包括通过更好的治疗分层和反应监测来改进早期诊断和初始管理，以及临床试验设计和联合治疗药物选择的改进。在本文中，我们讨论了所有这些领域所需的步骤，以充分利用新的治疗方案并打破玻璃天花板。